Emerging evidence exploring other inhibitors, such as the BD2-selective inhibitor apabetalone, suggests that inhibiting one BRD4 bromodomain over the other may improve the overall safety profile for HF patients requiring chronic therapy. The gene discussed is BRD4; the disease is hydrops fetalis.